Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity

Cytokine

Volumn 77, Issue , 2016, Pages 14-25

  Dirchwolf, Melisa ^a   Podhorzer, Ariel ^b   Marino, Monica ^c   Shulman, Carolina ^a   Cartier, Mariano ^c   Zunino, Moira ^a   Paz, Silvia ^a   Muñoz, Alberto ^c   Bocassi, Andrea ^a   Gimenez, Juan ^a   Di Pietro, Lucía ^a   Romero, Gustavo ^c   Fainboim, Hugo ^a   Fainboim, Leonardo ^b  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

Author keywords

Acute on chronic liver failure; Cirrhosis associated immune dysfunction; Immune paresis; Systemic inflammation

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARGENTINA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOPATHOLOGY; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; ACUTE-ON-CHRONIC LIVER FAILURE; BLOOD; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; BIOMARKERS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84945156666     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.10.006     Document Type: Article

References (45)

1. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006, 44:217-231.
2. Asrani S.K., O'Leary J.G. Acute-on-chronic liver failure. Clin. Liver Dis. 2014, 18:561-574.
3. Moreau R., Jalan R., Gines P., Pavesi M., Angeli P., Cordoba J., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013, 144:1426-1437. 37 e1-9.
4. Arroyo V., Moreau R., Jalan R., Gines P. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J. Hepatol. 2015, 62:S131-S143.
5. Mehta G., Mookerjee R.P., Sharma V., Jalan R. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int. 2015, 35:724-734.
6. Tazi K.A., Quioc J.J., Abdel-Razek W., Tellier Z., Guichard C., Ogier-Denis E., et al. Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: an ex vivo pilot study. Hepatol. Res. 2009, 39:706-715.
7. Wasmuth H.E., Kunz D., Yagmur E., Timmer-Stranghoner A., Vidacek D., Siewert E., et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J. Hepatol. 2005, 42:195-201.
8. Mookerjee R.P., Stadlbauer V., Lidder S., Wright G.A., Hodges S.J., Davies N.A., et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology (Baltimore, MD) 2007, 46:831-840.
9. Fiuza C., Salcedo M., Clemente G., Tellado J.M. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J. Infect. Dis. 2000, 182:526-533.
10. Bernsmeier C., Patel V., Tidswell R., Triantafyllou E., Singanayagam A., Khamri W., et al. P164 monocyte exhaustion: a mechanistic explanation for susceptibility to infection in liver failure. J. Hepatol. 2014, (60):S120-S121.
11. Albillos A., Lario M., Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 2014, 61:1385-1396.
12. Dirchwolf M., Ruf A.E. Role of systemic inflammation in cirrhosis: from pathogenesis to prognosis. World J. Hepatol. 2015, 7(16):1974-1981.
13. Buck M., Garcia-Tsao G., Groszmann R.J., Stalling C., Grace N.D., Burroughs A.K., et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology (Baltimore, MD) 2014, 59:1052-1059.
14. Giron-Gonzalez J.A., Martinez-Sierra C., Rodriguez-Ramos C., Macias M.A., Rendon P., Diaz F., et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int. 2004, 24:437-445.
15. Hu X., Ma S., Huang X., Jiang X., Zhu X., Gao H., et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J. Viral Hepat. 2011, 18:458-467.
16. Cazzaniga M., Dionigi E., Gobbo G., Fioretti A., Monti V., Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J. Hepatol. 2009, 51:475-482.
17. Behroozian R., Bayazidchi M., Rasooli J. Systemic Inflammatory response syndrome and MELD score in hospital outcome of patients with liver cirrhosis. Middle East J. Digestive Diseases 2012, 4:168-172.
18. Arroyo V., Garcia-Martinez R., Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J. Hepatol. 2014, 61:396-407.
19. Sipeki N., Antal-Szalmas P., Lakatos P.L., Papp M. Immune dysfunction in cirrhosis. World J. Gastroenterol. 2014, 20:2564-2577.
20. Wiest R., Lawson M., Geuking M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 2014, 60:197-209.
21. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
22. Jalan R., Fernandez J., Wiest R., Schnabl B., Moreau R., Angeli P., et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J. Hepatol. 2014, 60:1310-1324.
23. Chen H., Zhang D., Wang S., Wang X., Yang C. Significance of correlation between interferon-gamma and soluble intercellular adhesion molecule-1 and interleukin-17 in hepatitis B virus-related cirrhosis. Clinics Res. Hepatol. Gastroenterol. 2013, 37:608-613.
24. Attar B.M., Moore C.M., George M., Ion-Nedelcu N., Turbay R., Zachariah A., et al. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. World J. Gastroenterol. 2014, 20:2374-2382.
25. Jekarl D.W., Kim J.Y., Lee S., Kim M., Kim Y., Han K., et al. Diagnosis and evaluation of severity of sepsis via the use of biomarkers and profiles of 13 cytokines: a multiplex analysis. Clin. Chem. Lab. Med.: CCLM/FESCC 2015, 53:575-581.
26. Ono S., Ueno C., Aosasa S., Tsujimoto H., Seki S., Mochizuki H. Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am. J. Surg. 2001, 182:491-497.
27. Cavaillon J.M., Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care (London, England) 2006, 10:233.
28. Tiegs G., Lohse A.W. Immune tolerance: what is unique about the liver. J. Autoimmun. 2010, 34:1-6.
29. Garcia Ruiz P., Canora Lebrato J., Diez Ruiz A., Fuchs D., Wachter H. [Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis]. Med. Clin. 2004, 122:441-443.
30. Zimmermann H.W., Seidler S., Gassler N., Nattermann J., Luedde T., Trautwein C., et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 2011, 6:e21381.
31. Giraldo S., Sanchez J., Felty Q., Roy D. IL1B (interleukin 1, beta). Atlas Genet. Cytogenet. Oncol. Haematol. 2009, 13:273-275.
32. Liao W., Lin J.X., Leonard W.J. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 2011, 23:598-604.
33. Cuneo A.A., Autieri M.V. Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury. Curr. Vasc. Pharmacol. 2009, 7:267-276.
34. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-3109.
35. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
36. Willis C.R., Seamons A., Maxwell J., Treuting P.M., Nelson L., Chen G., et al. Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis. J. Inflammation (London, England) 2012, 9:39.
37. Dong R., Zheng S. Interleukin-8: a critical chemokine in biliary atresia. J. Gastroenterol. Hepatol. 2015, 30:970-976.
38. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
39. Yu J.J., Gaffen S.L. Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front. Biosci.: J. Virtual Lib. 2008, 13:170-177.
40. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 2007, 96:41-101.
41. Roberts A.W. G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors (Chur, Switzerland) 2005, 23:33-41.
42. Bhattacharya P., Thiruppathi M., Elshabrawy H.A., Alharshawi K., Kumar P., Prabhakar B.S. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 2015.
43. Bradley J.R. TNF-mediated inflammatory disease. J. Pathol. 2008, 214:149-160.
44. Driscoll K.E. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp. Lung Res. 1994, 20:473-490.
45. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res.: Official J. Int. Soc. Interferon Cytokine Res. 2009, 29:313-326.